It's a new hope to beat cancer.
And a stake in the battle between pharmaceutical companies.
"Conjugated antibodies" represent an emerging class of treatment whose first research dates back to the 1990s. They are molecules capable of precisely targeting cancer cells in order to destroy them: they deliver chemotherapy inside these cells. , which helps to preserve healthy cells and reduce the side effects of chemotherapy.
Read also: The new promises of immunotherapy
While they do not cure patients, these treatments have had encouraging results in lymphoma, leukemia and breast cancer.
Some doctors are already seeing them replace chemotherapy in the long term.
"All the laboratories positioned on the oncology market are interested in it,"
explains Éric Le Berrigaud, analyst at Bryan, Garnier & Co.
There are certain turns that should not be missed, as were before certain targeted therapies.
This article is for subscribers only.
You have 71% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in